The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice

Robert Stephens, Laura Johnston, Laura Servinsky, Bo Soo Kim, Mahendra Damarla

Research output: Contribution to journalArticle

Abstract

Severe sepsis and septic shock are frequent causes of the acute respiratory distress syndrome, and important sources of human mortality. Lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, plays a major role in the pathogenesis of severe sepsis and septic shock. LPS exposure induces the production of harmful reactive oxygen species, and the resultant oxidant injury has been implicated in the pathogenesis of both severe sepsis and ARDS. We previously showed that the tyrosine kinase inhibitor imatinib increases lung endothelial antioxidant enzymes and protects against pulmonary endothelial antioxidant injury. In the present study, we tested the hypothesis that imatinib would protect against lung injury and systemic inflammation caused by intravenous LPS in an intact mouse model of endotoxemia mimicking early sepsis. We found that intravenous LPS induced a significant increase in the activity of lung xanthine oxidoreductase (XOR), an enzyme which is a major source of reactive oxygen species and implicated in the pathogenesis of acute lung injury. Imatinib had no effect of LPS-induced XOR activity. However, pretreatment of mice with imatinib increased lung catalase activity and decreased intravenous LPS-induced lung oxidant injury as measured by γ-H2AX, a marker of oxidant-induced DNA damage, lung apoptosis, and pulmonary edema. Imatinib also attenuated systemic cytokine expression after intravenous LPS exposure. Finally, imatinib completely prevented mortality in an in vivo, intravenous LPS mouse model of endotoxemia and lung injury. These results support the testing of imatinib as a novel pharmacologic agent in the treatment of Gram-negative sepsis and sepsis-induced ARDS.

Original languageEnglish (US)
Article numbere12589
JournalPhysiological Reports
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Lung Injury
Protein-Tyrosine Kinases
Lipopolysaccharides
Sepsis
Lung
Oxidants
Xanthine Dehydrogenase
Endotoxemia
Septic Shock
Reactive Oxygen Species
Antioxidants
Mortality
Imatinib Mesylate
Acute Lung Injury
Adult Respiratory Distress Syndrome
Wounds and Injuries
Pulmonary Edema
Enzymes
Catalase
Cell Wall

Keywords

  • Endotoxin
  • imatinib
  • lung injury
  • sepsis

ASJC Scopus subject areas

  • Physiology (medical)
  • Physiology

Cite this

The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. / Stephens, Robert; Johnston, Laura; Servinsky, Laura; Kim, Bo Soo; Damarla, Mahendra.

In: Physiological Reports, Vol. 3, No. 11, e12589, 01.11.2015.

Research output: Contribution to journalArticle

@article{21ff4dcca4cd4f658b23b3893adb7509,
title = "The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice",
abstract = "Severe sepsis and septic shock are frequent causes of the acute respiratory distress syndrome, and important sources of human mortality. Lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, plays a major role in the pathogenesis of severe sepsis and septic shock. LPS exposure induces the production of harmful reactive oxygen species, and the resultant oxidant injury has been implicated in the pathogenesis of both severe sepsis and ARDS. We previously showed that the tyrosine kinase inhibitor imatinib increases lung endothelial antioxidant enzymes and protects against pulmonary endothelial antioxidant injury. In the present study, we tested the hypothesis that imatinib would protect against lung injury and systemic inflammation caused by intravenous LPS in an intact mouse model of endotoxemia mimicking early sepsis. We found that intravenous LPS induced a significant increase in the activity of lung xanthine oxidoreductase (XOR), an enzyme which is a major source of reactive oxygen species and implicated in the pathogenesis of acute lung injury. Imatinib had no effect of LPS-induced XOR activity. However, pretreatment of mice with imatinib increased lung catalase activity and decreased intravenous LPS-induced lung oxidant injury as measured by γ-H2AX, a marker of oxidant-induced DNA damage, lung apoptosis, and pulmonary edema. Imatinib also attenuated systemic cytokine expression after intravenous LPS exposure. Finally, imatinib completely prevented mortality in an in vivo, intravenous LPS mouse model of endotoxemia and lung injury. These results support the testing of imatinib as a novel pharmacologic agent in the treatment of Gram-negative sepsis and sepsis-induced ARDS.",
keywords = "Endotoxin, imatinib, lung injury, sepsis",
author = "Robert Stephens and Laura Johnston and Laura Servinsky and Kim, {Bo Soo} and Mahendra Damarla",
year = "2015",
month = "11",
day = "1",
doi = "10.14814/phy2.12589",
language = "English (US)",
volume = "3",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice

AU - Stephens, Robert

AU - Johnston, Laura

AU - Servinsky, Laura

AU - Kim, Bo Soo

AU - Damarla, Mahendra

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Severe sepsis and septic shock are frequent causes of the acute respiratory distress syndrome, and important sources of human mortality. Lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, plays a major role in the pathogenesis of severe sepsis and septic shock. LPS exposure induces the production of harmful reactive oxygen species, and the resultant oxidant injury has been implicated in the pathogenesis of both severe sepsis and ARDS. We previously showed that the tyrosine kinase inhibitor imatinib increases lung endothelial antioxidant enzymes and protects against pulmonary endothelial antioxidant injury. In the present study, we tested the hypothesis that imatinib would protect against lung injury and systemic inflammation caused by intravenous LPS in an intact mouse model of endotoxemia mimicking early sepsis. We found that intravenous LPS induced a significant increase in the activity of lung xanthine oxidoreductase (XOR), an enzyme which is a major source of reactive oxygen species and implicated in the pathogenesis of acute lung injury. Imatinib had no effect of LPS-induced XOR activity. However, pretreatment of mice with imatinib increased lung catalase activity and decreased intravenous LPS-induced lung oxidant injury as measured by γ-H2AX, a marker of oxidant-induced DNA damage, lung apoptosis, and pulmonary edema. Imatinib also attenuated systemic cytokine expression after intravenous LPS exposure. Finally, imatinib completely prevented mortality in an in vivo, intravenous LPS mouse model of endotoxemia and lung injury. These results support the testing of imatinib as a novel pharmacologic agent in the treatment of Gram-negative sepsis and sepsis-induced ARDS.

AB - Severe sepsis and septic shock are frequent causes of the acute respiratory distress syndrome, and important sources of human mortality. Lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, plays a major role in the pathogenesis of severe sepsis and septic shock. LPS exposure induces the production of harmful reactive oxygen species, and the resultant oxidant injury has been implicated in the pathogenesis of both severe sepsis and ARDS. We previously showed that the tyrosine kinase inhibitor imatinib increases lung endothelial antioxidant enzymes and protects against pulmonary endothelial antioxidant injury. In the present study, we tested the hypothesis that imatinib would protect against lung injury and systemic inflammation caused by intravenous LPS in an intact mouse model of endotoxemia mimicking early sepsis. We found that intravenous LPS induced a significant increase in the activity of lung xanthine oxidoreductase (XOR), an enzyme which is a major source of reactive oxygen species and implicated in the pathogenesis of acute lung injury. Imatinib had no effect of LPS-induced XOR activity. However, pretreatment of mice with imatinib increased lung catalase activity and decreased intravenous LPS-induced lung oxidant injury as measured by γ-H2AX, a marker of oxidant-induced DNA damage, lung apoptosis, and pulmonary edema. Imatinib also attenuated systemic cytokine expression after intravenous LPS exposure. Finally, imatinib completely prevented mortality in an in vivo, intravenous LPS mouse model of endotoxemia and lung injury. These results support the testing of imatinib as a novel pharmacologic agent in the treatment of Gram-negative sepsis and sepsis-induced ARDS.

KW - Endotoxin

KW - imatinib

KW - lung injury

KW - sepsis

UR - http://www.scopus.com/inward/record.url?scp=84977619970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977619970&partnerID=8YFLogxK

U2 - 10.14814/phy2.12589

DO - 10.14814/phy2.12589

M3 - Article

VL - 3

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 11

M1 - e12589

ER -